Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma.
暂无分享,去创建一个
[1] T. Tsuruo,et al. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo , 2004, Cancer Chemotherapy and Pharmacology.
[2] T. Saotome,et al. Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] T. Nakano,et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma , 1999, Cancer.
[4] K. Kubo,et al. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep. , 1998, Arzneimittel-Forschung.
[5] Y. Ohashi,et al. [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.
[6] T. Taguchi,et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Y. Nishiwaki,et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Ohno,et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.